

Antineoplastics

Vitamin D derivatives(19) Pneumocandins(4) APIs & Intermediates [Custom Synthesis](#)

Antineoplastics

Streptozocin [HOT]

Doxorubicin(Adriamycin)
hydrochloride

Mitomycin C

Actinomycin D

Tabine series

Decitabine

2-Deoxy-D-ribose [intermediate]

Fludarabine Phosphate

2-Fluoroadenosine [HOT]
[intermediate]


Zomib series

Bortezomib

(R)-BoroLeu-(+)-Pinanediol-
CF₃COOH [HOT] [intermediate]

Streptozocin,18883-66-4

Streptozocin



CAS

Molecular
Formula

Molecular
Weight

System
Name

Assay

View via
file

Specification

Appearance	Pale yellow crystalline powder	Complies
Solubility	Soluble in water	Complies
Identification		
UV Absorption	The UV absorption of 0.001% solution in water exhibits a maximum at about 228nm	Complies
IR Spectrum	IR Spectrum in potassium bromide dispersion of sample should be concordant with that of working standard spectrum	Complies
HPLC	Retention time of the sample should be concordant to the retention time of working standard	Complies
Element Analysis	Carbon, Nitrogen, Hydrogen	Complies
Melting point	121° C(DEC)	121° C(
[α] _D (c=1,H ₂ O)	+39°	+39°
α Isomer%	≥75%	85%
Residue On Ignition	NMT 0.1%	0.02%
Heavy metals	Max 20ppm	Complies
Loss On Drying	NMT 1.0%	0.33%
Single Impurity	NMT 0.5%	0.1%
Total Impurity	NMT 1.0%	0.2%
Assay	99%	99.5%

Related Antineoplastic Antibiotics

[Streptozocin \[HOT\]](#)

[Mitomycin C \[HOT\]](#)

[Doxoru](#)

[Actinomycin D \[HOT\]](#)

[Bleomycin sulphate](#)

Patent Disclaimer

PD1

Products protected by valid patents are not of such products constitutes a patent infringe products and technologies that are available, may be developed or produced for internal ai

- PD2 Sales of products are limited to those allowed under this patent. The patent includes Research and development quantities.
- PD3 the buyer assumes responsibility of all patent rights for Lanos Pharmaceutical Co.,Ltd product(s).
- PD4 R&D use in accordance with (1) 35 USC 271 Japanese Patent Law in Japan; (2) Section 1 of the German Patent Law in Germany; (3) Section 1 of the German Patent Law in Germany; (iv) Section 60, Paragraph 5b of the German Patent Law in Germany; (v) Sections 55.2(1) and 55.2(6) and other provisions of the German Patent Law in Germany; (5) Section 68B of the Patents Act of 1953 in the United Kingdom as amended by the Statutes Amendment Bill of 1977 and any other law as may be or become applicable in the future in any country. The laws and rules as may apply in various other countries.

Friend link: www.meilipharma.com